S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)

AbbVie Earnings Date, Estimates, & History

$107.07
-0.29 (-0.27 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$106.44
$108.05
50-Day Range
$106.40
$120.78
52-Week Range
$79.11
$121.53
Volume5.45 million shs
Average Volume7.04 million shs
Market Capitalization$189.21 billion
P/E Ratio28.86
Dividend Yield4.84%
Beta0.82

Earnings Summary

Upcoming
Earnings Date
Oct. 29
Estimated

Actual EPS
(Jul. 29)
$3.11
Beat By $0.02

Consensus EPS
(Jul. 29)
$3.09

Last Year's Q3 EPS
(7/31/2020)
$2.34

AbbVie Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AbbVie Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

AbbVie (NYSE:ABBV) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20213$2.79$3.02$2.90 
Q2 20213$3.06$3.24$3.13$3.050-3.090
Q3 20213$3.15$3.27$3.21 
Q4 20213$3.36$3.47$3.40 
FY 202112$12.36$13.00$12.65
Q1 20222$3.13$3.29$3.21 
Q2 20222$3.31$3.54$3.43 
Q3 20222$3.62$3.73$3.68 
Q4 20222$3.59$3.91$3.75 
FY 20228$13.65$14.47$14.06

ABBV Earnings Information

AbbVie last announced its earnings data on July 29th, 2021. The reported $3.11 earnings per share for the quarter, beating the consensus estimate of $3.09 by $0.02. The firm had revenue of $13.96 billion for the quarter, compared to the consensus estimate of $13.64 billion. Its revenue for the quarter was up 33.9% compared to the same quarter last year. AbbVie has generated $10.56 earnings per share over the last year ($3.71 diluted earnings per share) and currently has a price-to-earnings ratio of 28.9. Earnings for AbbVie are expected to grow by 9.97% in the coming year, from $12.64 to $13.90 per share. AbbVie has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, October 29th, 2021 based off prior year's report dates.

AbbVie (NYSE:ABBV) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
10/29/2021
(Estimated)
        
7/29/20216/30/2021$3.09$3.11+$0.02$5.80$13.64 billion$13.96 billion      
4/29/20213/31/2021$2.83$2.95+$0.12$3.91$12.84 billion$13.01 billion  
2/2/202112/31/2020$2.85$2.92+$0.07$5.83$13.70 billion$13.86 billion  
10/30/20209/30/2020$2.75$2.83+$0.08$4.37$12.71 billion$12.88 billion    
7/31/20206/30/2020$2.20$2.34+$0.14$5.14$10.14 billion$10.43 billion    
5/1/20203/31/2020$2.25$2.42+$0.17$2.82$8.31 billion$8.62 billion  
2/7/202012/31/2019$2.19$2.21+$0.02$2.54$8.68 billion$8.70 billion  
11/1/2019Q3 2019$2.29$2.33+$0.04$3.40$8.37 billion$8.48 billion    
7/26/2019Q2 2019$2.21$2.26+$0.05$4.03$8.09 billion$8.26 billion  
4/25/2019Q1 2019$2.06$2.14+$0.08$2.63$7.81 billion$7.83 billion  
1/25/201912/31/2018$1.92$1.90($0.02)$5.03$8.37 billion$8.31 billion  
11/2/20189/30/2018$2.01$2.14+$0.13$2.47$8.23 billion$8.24 billion  
7/27/20186/30/2018$1.98$2.00+$0.02$2.74$8.22 billion$8.28 billion
4/26/2018Q1 2018$1.79$1.87+$0.08$2.00$7.60 billion$7.93 billion
1/26/2018Q4 2017$1.44$1.48+$0.04$2.93$7.53 billion$7.74 billion  
10/27/2017Q3 2017$1.39$1.41+$0.02$1.81$7.00 billion$7.00 billion
7/28/2017Q2 2017$1.40$1.42+$0.02$1.65$6.93 billion$6.94 billion
4/27/2017Q1 2017$1.2620$1.28+$0.0180$1.50$6.49 billion$6.54 billion
1/27/2017Q416$1.20$1.20$1.55$6.92 billion$6.78 billion  
10/28/2016Q316$1.21$1.21$1.45$6.55 billion$6.43 billion  
7/29/2016Q216$1.20$1.26+$0.06$1.54$6.20 billion$6.43 billion  
4/28/2016Q116$1.14$1.15+$0.01$1.47$6.03 billion$5.96 billion  
1/29/2016Q415$1.12$1.13+$0.01$1.34$6.41 billion$6.36 billion  
10/30/2015Q315$1.08$1.13+$0.05$1.52$5.90 billion$4.94 billion  
7/24/2015Q215$1.06$1.08+$0.02$1.33$5.60 billion$5.48 billion  
4/23/2015Q115$0.85$0.94+$0.09$1.25$718.50 million$5.04 billion  
1/30/2015Q414$0.86$0.89+$0.03$2.29$5.34 billion$5.45 billion  
10/31/2014Q3$0.77$0.89+$0.12$1.47$4.82 million$5.02 million  
7/25/2014Q214$0.76$0.82+$0.06$0.96$4.70 billion$4.93 billion  
4/25/2014Q114$0.68$0.71+$0.03$0.83$4.33 billion$4.56 billion  
1/31/2014Q4 2013$0.83$0.82($0.01)$0.94$5.10 billion$5.11 billion  
10/25/2013Q3 2013$0.78$0.82+$0.04$1.04$4.52 billion$4.66 billion  
7/26/2013Q2 2013$0.79$0.82+$0.03$0.98$4.54 billion$4.69 billion  
4/26/2013Q1 2013$0.66$0.68+$0.02$0.76$4.17 billion$4.33 billion  
(Earnings results data provided by Zacks Investment Research)
speech bubbles
speech bubbles











AbbVie (NYSE:ABBV) Earnings Frequently Asked Questions

When is AbbVie's earnings date?

AbbVie has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, October 29th, 2021 based off last year's report dates. Learn more on ABBV's earnings history

Did AbbVie beat their earnings estimates last quarter?

In the previous quarter, AbbVie (NYSE:ABBV) reported $3.11 earnings per share (EPS) to beat the analysts' consensus estimate of $3.09 by $0.02. Learn more on ABBV's earnings details

How can I listen to AbbVie's earnings conference call?

The conference call for AbbVie's latest earnings report can be listened to online. Listen to Conference Call

How can I read AbbVie's conference call transcript?

The conference call transcript for AbbVie's latest earnings report can be read online. Read Transcript

How can I view AbbVie's earnings report?

AbbVie's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does AbbVie generate each year?

AbbVie (NYSE:ABBV) has a recorded annual revenue of $45.80 billion.

How much profit does AbbVie generate each year?

AbbVie (NYSE:ABBV) has a recorded net income of $4.62 billion. ABBV has generated $10.56 earnings per share over the last four quarters.

What is AbbVie's price-to-earnings ratio?

AbbVie (NYSE:ABBV) has a trailing price-to-earnings ratio of 28.86 and a forward price-to-earnings ratio of 8.47. The price/earnings-to-growth ratio is 2.01.

What is AbbVie's EPS forecast for next year?

AbbVie's earnings are expected to grow from $12.64 per share to $13.90 per share in the next year, which is a 9.97% increase.

This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.